Want to see HK:6618 full AI Analyst Report?
6618 Stock Chart & Stats
HK$37.00
HK$0.78(2.11%)
At close: 4:00 PM EDT
HK$37.00
HK$0.78(2.11%)
Day’s Range― - ―
52-Week RangeHK$31.84 - HK$71.70
Previous CloseN/A
Volume4.55M
Average Volume (3M)7.60M
Market Cap
HK$126.52B
Enterprise ValueHK$124.80K
Total Cash (Recent Filing)HK$48.15B
Total Debt (Recent Filing)HK$636.29M
Price to Earnings (P/E)20.2
Beta1.40
Next Earnings
Aug 13, 2026EPS Estimate
1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.68
Shares Outstanding3,211,075,200
10 Day Avg. Volume6,883,323
30 Day Avg. Volume7,596,953
Financial Highlights & Ratios
PEG Ratio1.02
Price to Book (P/B)2.65
Price to Sales (P/S)2.17
P/FCF Ratio16.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$67.25Price Target Upside81.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)1.8
Revenue Forecast (FY)HK$86.38B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained double‑digit revenue growth across multiple quarters demonstrates durable demand and successful go‑to‑market execution. This momentum supports scale economics, funds continued investment in supply chain and AI, and provides a multi‑quarter runway for margin and service expansion.
Balance Sheet StrengthAn exceptionally low leverage profile and rising equity provide strong financial flexibility. This conservatism enables the company to fund R&D, AI initiatives and measured offline expansion without heavy refinancing risk, offering downside protection and strategic optionality over several quarters.
AI & Product PipelineRapid scaling of AI services and an expanding drug launch cadence create structural advantages: higher platform stickiness, potential new service revenue streams, and stronger clinical partnerships. These capabilities can compound as multi‑year drivers if commercialized effectively.
Bears Say
Cash Flow ConsistencyA reset of free cash flow to zero indicates a meaningful step‑up in investment or working capital that reduces near‑term financial flexibility. This uneven cash conversion versus earnings raises execution risk for capital allocation, dividends or buybacks over the medium term.
Revenue ConcentrationHigh dependence on direct sales concentrates revenue exposure to a limited set of categories, suppliers and channel dynamics. That concentration increases vulnerability to category disruption, supplier pricing or inventory shocks and limits the protective diversification of the business mix.
AI Monetization UncertaintyWhile AI engagement metrics are impressive, the path to reliable monetization—particularly for B2B doctor‑facing tools—remains unproven. If commercialization stalls, the company may face longer payback on R&D and higher S&M to drive adoption, pressuring near‑term margins.
JD Health International, Inc. News
6618 FAQ
What was JD Health International, Inc.’s price range in the past 12 months?
JD Health International, Inc. lowest stock price was HK$31.84 and its highest was HK$71.70 in the past 12 months.
What is JD Health International, Inc.’s market cap?
JD Health International, Inc.’s market cap is HK$126.52B.
When is JD Health International, Inc.’s upcoming earnings report date?
JD Health International, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 11 days.
How were JD Health International, Inc.’s earnings last quarter?
JD Health International, Inc. released its earnings results on Mar 05, 2026. The company reported HK$1.086 earnings per share for the quarter, beating the consensus estimate of HK$0.755 by HK$0.331.
Is JD Health International, Inc. overvalued?
According to Wall Street analysts JD Health International, Inc.’s price is currently Undervalued.
Does JD Health International, Inc. pay dividends?
JD Health International, Inc. does not currently pay dividends.
What is JD Health International, Inc.’s EPS estimate?
JD Health International, Inc.’s EPS estimate is 1.36.
How many shares outstanding does JD Health International, Inc. have?
JD Health International, Inc. has 3,211,075,200 shares outstanding.
What happened to JD Health International, Inc.’s price movement after its last earnings report?
JD Health International, Inc. reported an EPS of HK$1.086 in its last earnings report, beating expectations of HK$0.755. Following the earnings report the stock price went down -6.219%.
Which hedge fund is a major shareholder of JD Health International, Inc.?
Currently, no hedge funds are holding shares in HK:6618
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JD Health International, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$67.25 (81.76% Upside)
HK$67.25 (81.76% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.80%
Trailing 12-Months
Company Description
JD Health International, Inc.
JD Health International Inc., functioning as an investment holding entity, runs an expansive digital healthcare platform across the People's Republic of China. The company supplies a diverse range of pharmaceutical and wellness products, such as over-the-counter and prescription medications, medical devices, and health supplements. These goods are distributed through both direct sales and an extensive online retail pharmacy network. Beyond product offerings, its comprehensive service suite includes virtual medical consultations, patient referrals to hospitals and doctors, health screening programs, genetic testing, and beauty care services. Additionally, it develops intelligent healthcare and wellness management solutions, alongside providing technical support and advertising services. The platform also facilitates access to various medical provisions, including general health examinations, cosmetic medical procedures, vaccination bookings, dental treatments, and nucleic acid testing. Incorporated in 2018 and headquartered in Beijing, People's Republic of China, JD Health International Inc. is a subsidiary of JD Jiankang Limited.
6618 Stock 12 Month Forecast
Average Price Target
HK$67.25
▲(81.76% Upside)
Technical Analysis
Kindstar Globalgene Technology, Inc.
―
Jinxin Fertility Group Ltd.
―
C-MER Eye Care Holdings Limited
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―